Should Incyte Investors Be Panicked?

Editor's note: The following video incorrectly stated that a patient taking Incyte's drug Jakafi passed away from a fatal brain infection. The patient developed PML, but is still alive. The Fool regrets the error. 

Shares of biotech Incyte (NASDAQ: INCY  ) came down hard today, after news that the company's drug Jakafi may have weakened the immune system of one patient in the U.K. enough to allow a rare type of viral brain disease to take hold. In this video, Motley Fool health-care analyst David Williamson gives investors some advice that may temper their panic a bit.

While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2319270, ~/Articles/ArticleHandler.aspx, 11/26/2014 9:08:07 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement